Saniona publishes its interim report for the second quarter of 2023
| Three Months Ended June 30, 2023 (2022) | Six Months Ended June 30, 2023 (2022) |
| Revenue was SEK 3.9 M (3.0 M) | Revenue was SEK 6.0 M (9.6 M) |
| Operating profit/loss was SEK -21.8 M (-91.8 M) | Operating profit/loss was SEK -42.9 M (-225.0 M) |
| Net profit/loss was SEK -21.2 M (-88.6 M) | Net profit/loss was SEK -43.0 M (-221.9 M) |
| Basic earnings/loss per share was SEK -0.34 (-1.42) | Basic earnings/loss per share was SEK -0.69 (-3.56) |
| Diluted earnings/loss per share were SEK -0.34 (-1.42) | Diluted earnings/loss per share were SEK -0.69 (-3.56) |
Business highlights in Q2 2023
- Pierandrea Muglia was at the Annual General Meeting May 25, 2023, elected as a new ordinary board member.
Significant events after the reporting period
- On July 17, Saniona announced a new collaboration agreement with AstronauTx in Alzheimer’s disease.
- In August, Saniona announced a change to the terms of the loan agreement with Formue Nord. The parties agreed to reduce the loan value, through a repayment of 3 MSEK by Saniona and a conversion of 10 MSEK into shares at 8.50 SEK per share, and changed the maturity date to January 31, 2025.
Comments from the CEO
“We have established an additional partnership with the research collaboration with AstronauTx in Alzheimer’s disease. Our objectives are unchanged, and we are working diligently with potential partners with the aim of reaching an additional partnership this year.”